Reuters (June 24)
“A scramble for lithium” is creating “new risks for electric-car makers. Breathtaking prices are prompting the industry to find new ways to secure the crucial battery ingredient,” often through “direct contracts with miners and refiners” with “options to buy 100% or more of a project’s planned production capacity.” Although “vertical integration is tempting when times are tough,” it can leave buyers overstretched and “dealmaking under duress makes miscalculations more likely.”
Tags: Battery, Breathtaking, Buyers, Capacity, Dealmaking, Duress, EVs, Lithium, Miners, Overstretched, Prices, Production, Refiners, Risks, Scramble, Vertical integration
Financial Times (May 13)
For some time, “private equity firms have set their sights on the many profitable yet unloved parts of corporate Japan that sit under the umbrellas of conglomerates such as Toshiba, Hitachi and others.” Currently, “the attention on Japan could not be any greater. Much of the ‘dry powder’ sitting in funds raised for Asian dealmaking is now less likely to be used in China than to back increasingly ambitious deals in Japan.”
Tags: Ambitious, Asian, China, Conglomerates, Dealmaking, Dry-powder, Funds, Hitachi, Japan, Private equity, Profitable, Toshiba, Unloved
Investment Week (March 28)
Global dealmaking has dropped “to its lowest level since the start of the Covid-19 pandemic…. Just over $1trn of deals were struck in the first quarter of 2022, nearly a quarter less than the same period last year.” Primary factors behind slowing M&A activity appear to be “tougher regulations on both sides of the Atlantic, soaring inflation and Russia’s invasion of Ukraine.”
Tags: 2022, COVID-19, Dealmaking, Global, Inflation, M&A, Outbreak, Pandemic, Q1, Regulation, Russia, Slowing, Soaring, Tougher, Ukraine, War
The Detroit News (June 22)
“Suddenly, in just a matter of a few months, the vast dealmaking machinery that caters to wealthy entrepreneurs has started buzzing with a level of activity that some industry veterans say they haven’t seen before, potentially setting up a cascade of sales for later this year. A combination of high valuations on companies and potentially higher taxes in the future is proving to be a potent motivator.”
Tags: Cascade, Companies, Dealmaking, Entrepreneurs, Future, High valuations, Higher taxes, Sales, Wealthy
Reuters (January 2)
“CEOs increasingly talk a good game on climate change, but the financial implications of global warming have played a small role in dealmaking so far. That will change in the year ahead.”
Businessweek (May 3)
President Trump “wrote a book on dealmaking, only this time nuclear war and peace will hang in the balance, rather than a real estate contract. And on the evidence so far, his sparring partner Kim Jong Un has mastered The Art of the Deal, too.” For example, “Kim has already changed the conversation while giving away very little, beyond a moratorium on nuclear tests that may no longer be needed…. The summit alone is a public-relations coup for Kim. A one-on-one meeting with the U.S. president has been a long-held North Korean goal.”
Tags: Dealmaking, Kim Jong Un, Moratorium, Nuclear tests, Nuclear war, Peace, Trump
Bloomberg (April 3)
“Japan Inc. is on track to overtake China in overseas dealmaking for the first time in six years.” According to Bloomberg data, “Japanese companies have announced $26.9 billion of overseas acquisitions this year, compared with $16.5 billion by Chinese buyers.” The reversal is fueled by “a hunt for growth at Japanese firms…at a time when China’s most prolific acquirers have been hobbled by regulatory probes and new outbound investment rules.”
Tags: Acquirers, Acquisitions, China, Dealmaking, Growth, Japan Inc., Outbound investment, Overseas, Regulatory probes, Reversal
Financial Times (May 12)
There’s little obvious business sense to Pfizer’s proposed takeover of AstraZeneca. Strategically, there’s not much to be gained aside from effecting a change of tax domicile. “Pfizer’s dealmaking history is moreover a deeply dispiriting one…. Despite having spent some $240bn on three big acquisitions since 2000, its market capitalisation is just $185bn today. Meanwhile the Dow Jones index is more than 40 per cent higher.” AstraZeneca’s directors must proceed warily. This is about more than the potential short-term profit to existing shareholders.
Tags: Acquisitions, AstraZeneca, Dealmaking, Directors, Dow Jones, Market-cap, Pfizer, Profit, Shareholders, Short term, Strategy, Takeover, Tax domicile
